Navigation Links
Wisconsin firms make acquisitions for Check 21 readiness

In preparation for the Check Clearing for the 21st Century Act, commonly called Check 21, two Wisconsin firms have acquired companies that specialize in electronic check imaging.

Check 21, which will come into effect on October 28, is designed to improve the efficiency of the payments system by legalizing the use of digital copies of checks in place of the ph......

Full article >>>
'"/>

Source:wistechnology.com By WTN News 10/18/04


Page: 1 2

Related biology technology :

1. To be a player in the "Knowledge Economy," Wisconsin needs more tech workers
2. Federal bioenergy lab will give Wisconsin a chance to shine
3. Breaking down Wisconsins angel capital numbers
4. Innovation featured in NE Wisconsin Roundtable
5. Visions: Broderick says Wisconsin should be in top third in venture capital
6. Wisconsin building toward the major leagues of venture capital
7. Wisconsin Supreme Court to hear Menasha software case
8. Wisconsin applicants urged to pursue DOE funding for cellulosic biomass
9. Legislature should look to Wisconsins natural energy advantages
10. Stem cells get most attention, but they are only part of Wisconsins bio-portfolio
11. BIO 2007: Wisconsin makes its presence felt
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Wisconsin firms make acquisitions for Check readiness

Breaking Biology Technology:ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 3Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3
Other Biology Technology:Women's Surgery Recorded for the First Time on '4K' Digital Cinema is Presented at the AAGL Congress 2CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 2CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 3CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 4CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 5CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 6CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 7CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 8CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 9CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 10CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 11Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 2Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 3Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 4Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 5Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 6Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 7Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 8Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 9Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 10Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 11Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 12Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 13Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 14